Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response.

Mairinger F, Bankfalvi A, Schmid KW, Mairinger E, Mach P, Walter RF, Borchert S, Kasimir-Bauer S, Kimmig R, Buderath P.

Cancer Manag Res. 2019 Nov 12;11:9571-9583. doi: 10.2147/CMAR.S219872. eCollection 2019.

2.

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer.

Buderath P, Schwich E, Jensen C, Horn PA, Kimmig R, Kasimir-Bauer S, Rebmann V.

Front Oncol. 2019 Oct 15;9:1015. doi: 10.3389/fonc.2019.01015. eCollection 2019.

3.

Localization of PD-L1 on single cancer cells by iSERS microscopy with Au/Au core/satellite nanoparticles.

Stepula E, König M, Wang XP, Levermann J, Schimming T, Kasimir-Bauer S, Schilling B, Schlücker S.

J Biophotonics. 2019 Oct 12:e201960034. doi: 10.1002/jbio.201960034. [Epub ahead of print]

PMID:
31605507
4.

Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.

Buderath P, Mairinger F, Mairinger E, Böhm K, Mach P, Schmid KW, Kimmig R, Kasimir-Bauer S, Bankfalvi A, Westerwick D, Hager T.

Int J Gynecol Cancer. 2019 Nov;29(9):1389-1395. doi: 10.1136/ijgc-2019-000609. Epub 2019 Sep 5.

PMID:
31492714
5.

Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer.

Schwich E, Rebmann V, Horn PA, Celik AA, Bade-Döding C, Kimmig R, Kasimir-Bauer S, Buderath P.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1106. doi: 10.3390/cancers11081106.

6.

Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.

Keup C, Benyaa K, Hauch S, Sprenger-Haussels M, Tewes M, Mach P, Bittner AK, Kimmig R, Hahn P, Kasimir-Bauer S.

Cell Mol Life Sci. 2019 Jun 28. doi: 10.1007/s00018-019-03189-z. [Epub ahead of print]

PMID:
31254045
7.

HLA-G 3' untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer.

Schwich E, Rebmann V, Michita RT, Rohn H, Voncken JW, Horn PA, Kimmig R, Kasimir-Bauer S, Buderath P.

Sci Rep. 2019 Apr 1;9(1):5407. doi: 10.1038/s41598-019-41900-z.

8.

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Aktas B, Fasching PA, Hartkopf A, Janni W, Kasimir-Bauer S, Pantel K, Schön G, Rack B, Riethdorf S, Solomayer EF, Fehm T, Müller V.

Sci Rep. 2019 Feb 19;9(1):2318. doi: 10.1038/s41598-018-37259-2.

9.

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer.

Keup C, Storbeck M, Hauch S, Hahn P, Sprenger-Haussels M, Tewes M, Mach P, Hoffmann O, Kimmig R, Kasimir-Bauer S.

Cancers (Basel). 2019 Feb 18;11(2). pii: E238. doi: 10.3390/cancers11020238.

10.

Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.

König L, Mairinger FD, Hoffmann O, Bittner AK, Schmid KW, Kimmig R, Kasimir-Bauer S, Bankfalvi A.

BMC Cancer. 2019 Feb 4;19(1):120. doi: 10.1186/s12885-019-5320-2.

11.

Development and Validation of Multiplex Liquid Bead Array Assay for the Simultaneous Expression of 14 Genes in Circulating Tumor Cells.

Parisi C, Markou A, Strati A, Kasimir-Bauer S, Lianidou ES.

Anal Chem. 2019 Mar 5;91(5):3443-3451. doi: 10.1021/acs.analchem.8b04975. Epub 2019 Feb 11.

PMID:
30663875
12.

Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.

Rachner TD, Kasimir-Bauer S, Göbel A, Erdmann K, Hoffmann O, Browne A, Wimberger P, Rauner M, Hofbauer LC, Kimmig R, Bittner AK.

Clin Cancer Res. 2019 Feb 15;25(4):1369-1378. doi: 10.1158/1078-0432.CCR-18-2482. Epub 2018 Nov 13.

PMID:
30425091
13.

Extracellular vesicle-associated miRNAs in ovarian cancer - design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance.

Kuhlmann JD, Chebouti I, Kimmig R, Buderath P, Reuter M, Puppel SH, Wimberger P, Kasimir-Bauer S.

Clin Chem Lab Med. 2019 Jun 26;57(7):1053-1062. doi: 10.1515/cclm-2018-1048.

PMID:
30422797
14.

Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.

Giannopoulou L, Zavridou M, Kasimir-Bauer S, Lianidou ES.

Transl Res. 2019 Mar;205:77-91. doi: 10.1016/j.trsl.2018.10.003. Epub 2018 Oct 12. Review.

PMID:
30391474
15.

The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching PA, Aktas B, Kasimir-Bauer S, Hartkopf A, Solomayer EF, Fehm T, Müller V.

Breast Cancer Res Treat. 2018 Nov;172(1):93-104. doi: 10.1007/s10549-018-4882-z. Epub 2018 Jul 12.

PMID:
30003393
16.

ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.

Giannopoulou L, Mastoraki S, Buderath P, Strati A, Pavlakis K, Kasimir-Bauer S, Lianidou ES.

Gynecol Oncol. 2018 Aug;150(2):355-360. doi: 10.1016/j.ygyno.2018.05.026. Epub 2018 May 26.

PMID:
29807696
17.

RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients.

Keup C, Mach P, Aktas B, Tewes M, Kolberg HC, Hauch S, Sprenger-Haussels M, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2018 Jul;64(7):1054-1062. doi: 10.1373/clinchem.2017.283531. Epub 2018 May 16.

18.

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.

Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching PA, Kasimir-Bauer S, Milde-Langosch K, Pantel K, Rack B, Riethdorf S, Solomayer EF, Witzel I, Müller V.

BMC Cancer. 2018 May 8;18(1):541. doi: 10.1186/s12885-018-4282-0.

19.

Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy.

König L, Kasimir-Bauer S, Bittner AK, Hoffmann O, Wagner B, Santos Manvailer LF, Kimmig R, Horn PA, Rebmann V.

Oncoimmunology. 2017 Sep 27;7(1):e1376153. doi: 10.1080/2162402X.2017.1376153. eCollection 2017.

20.

Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy.

Zheng H, Bae Y, Kasimir-Bauer S, Tang R, Chen J, Ren G, Yuan M, Esposito M, Li W, Wei Y, Shen M, Zhang L, Tupitsyn N, Pantel K, King C, Sun J, Moriguchi J, Jun HT, Coxon A, Lee B, Kang Y.

Cancer Cell. 2017 Dec 11;32(6):731-747.e6. doi: 10.1016/j.ccell.2017.11.002.

21.

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V.

Sci Rep. 2017 Dec 11;7(1):17307. doi: 10.1038/s41598-017-17514-8.

22.

Fast and reproducible iSERS microscopy of single HER2-positive breast cancer cells using gold nanostars as SERS nanotags.

Wang XP, Walkenfort B, König M, König L, Kasimir-Bauer S, Schlücker S.

Faraday Discuss. 2017 Dec 4;205:377-386. doi: 10.1039/c7fd00135e.

PMID:
28902197
23.

Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer.

Bredemeier M, Edimiris P, Mach P, Kubista M, Sjöback R, Rohlova E, Kolostova K, Hauch S, Aktas B, Tewes M, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2017 Oct;63(10):1585-1593. doi: 10.1373/clinchem.2016.269605. Epub 2017 Aug 3.

24.

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.

Giannopoulou L, Kasimir-Bauer S, Lianidou ES.

Clin Chem Lab Med. 2018 Jan 26;56(2):186-197. doi: 10.1515/cclm-2017-0019. Review.

25.

Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V.

Anticancer Res. 2017 Jun;37(6):3117-3128.

PMID:
28551653
26.

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.

Chebouti I, Kasimir-Bauer S, Buderath P, Wimberger P, Hauch S, Kimmig R, Kuhlmann JD.

Oncotarget. 2017 Jul 25;8(30):48820-48831. doi: 10.18632/oncotarget.16179.

27.

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.

Chebouti I, Kuhlmann JD, Buderath P, Weber S, Wimberger P, Bokeloh Y, Hauch S, Kimmig R, Kasimir-Bauer S.

Oncotarget. 2017 Apr 11;8(15):24303-24313. doi: 10.18632/oncotarget.13286.

28.

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.

Bredemeier M, Kasimir-Bauer S, Kolberg HC, Herold T, Synoracki S, Hauch S, Edimiris P, Bankfalvi A, Tewes M, Kimmig R, Aktas B.

Mol Med Rep. 2017 May;15(5):2957-2968. doi: 10.3892/mmr.2017.6415. Epub 2017 Mar 30.

29.

RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.

Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou ES.

Oncotarget. 2017 Mar 28;8(13):21429-21443. doi: 10.18632/oncotarget.15249.

30.

Evaluation of a novel ELISA for the tumor-associated antigen CA 72-4 in patients with ovarian cancer.

Buderath P, Kasimir-Bauer S, Aktas B, Rasch J, Kimmig R, Zeller T, Heubner M.

Future Sci OA. 2016 Oct 12;2(4):FSO145. doi: 10.4155/fsoa-2016-0040. eCollection 2016 Dec.

31.

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.

Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M; DETECT Study Group.

BMC Cancer. 2016 Jul 25;16:522. doi: 10.1186/s12885-016-2587-4.

32.

iSERS microscopy guided by wide field immunofluorescence: analysis of HER2 expression on normal and breast cancer FFPE tissue sections.

Wang XP, Zhang Y, König M, Papadopoulou E, Walkenfort B, Kasimir-Bauer S, Bankfalvi A, Schlücker S.

Analyst. 2016 Aug 15;141(17):5113-9. doi: 10.1039/c6an00927a.

PMID:
27302205
33.

Serum concentrations of soluble B7-H4 in early pregnancy are elevated in women with preterm premature rupture of fetal membranes.

Mach P, Köninger A, Wicherek L, Kimmig R, Kasimir-Bauer S, Birdir C, Schmidt B, Gellhaus A.

Am J Reprod Immunol. 2016 Aug;76(2):149-54. doi: 10.1111/aji.12527. Epub 2016 Jun 15.

PMID:
27302185
34.

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.

Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, Schellbach D, Wagner J, Kimmig R, Kasimir-Bauer S.

Oncotarget. 2016 Jul 5;7(27):41677-41690. doi: 10.18632/oncotarget.9528.

35.

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?

Kasimir-Bauer S, Reiter K, Aktas B, Bittner AK, Weber S, Keller T, Kimmig R, Hoffmann O.

Sci Rep. 2016 May 23;6:26355. doi: 10.1038/srep26355.

36.

Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?

Chebouti I, Blassl C, Wimberger P, Neubauer H, Fehm T, Kimmig R, Kasimir-Bauer S.

Oncotarget. 2016 May 3;7(18):26454-64. doi: 10.18632/oncotarget.8524.

37.

Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies.

Kuessel L, Kasimir-Bauer S, Zeillinger R, Pateisky P, Ott J, Zeisler H, Birdir C.

Hypertens Pregnancy. 2016 Aug;35(3):323-9. doi: 10.3109/10641955.2016.1143487. Epub 2016 Mar 1.

PMID:
26930176
38.

Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.

Kasimir-Bauer S, Bittner AK, König L, Reiter K, Keller T, Kimmig R, Hoffmann O.

Breast Cancer Res. 2016 Feb 12;18(1):20. doi: 10.1186/s13058-016-0679-3.

39.

The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients.

König L, Kasimir-Bauer S, Hoffmann O, Bittner AK, Wagner B, Manvailer LF, Schramm S, Bankfalvi A, Giebel B, Kimmig R, Horn PA, Rebmann V.

Hum Immunol. 2016 Sep;77(9):791-9. doi: 10.1016/j.humimm.2016.01.002. Epub 2016 Jan 12.

PMID:
26796737
40.

Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects.

Heubner M, Wimberger P, Kasimir-Bauer S, Singer BB, Ruf P, Kimmig R, Siffert W.

Arch Gynecol Obstet. 2015 Dec;292(6):1367-72. doi: 10.1007/s00404-015-3802-2. Epub 2015 Jun 27.

PMID:
26115884
41.

Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.

Hoffmann O, Schroer-Zuendorf IA, Kasimir-Bauer S, Oberhoff C, Kimmig R, Heubner M.

Arch Gynecol Obstet. 2015 Nov;292(5):1117-25. doi: 10.1007/s00404-015-3748-4. Epub 2015 May 19.

PMID:
25986892
42.

Maternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia.

Birdir C, Janssen K, Stanescu AD, Enekwe A, Kasimir-Bauer S, Gellhaus A, Kimmig R, Köninger A.

Arch Gynecol Obstet. 2015 Nov;292(5):1033-42. doi: 10.1007/s00404-015-3745-7. Epub 2015 May 15.

PMID:
25975456
43.

Changes in the Blood Serum Levels of the Costimulatory Soluble B7-H4 Molecule in Pregnant Women During the Peripartal Phase.

Mach P, Gellhaus A, Wicherek L, Schmidt B, Kimmig R, Kasimir-Bauer S, Köninger A.

Am J Reprod Immunol. 2015 Sep;74(3):209-15. doi: 10.1111/aji.12392. Epub 2015 Apr 24.

PMID:
25907449
44.

Change of anti-Mullerian-hormone levels during follicular phase in PCOS patients.

Köninger A, Koch L, Enekwe A, Birdir C, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.

Gynecol Endocrinol. 2015 Jan;31(1):26-30. doi: 10.3109/09513590.2014.959436. Epub 2014 Sep 15.

PMID:
25222840
45.

Intraindividual right-left comparison of sonographic features in polycystic ovary syndrome (PCOS) diagnosis.

Köninger A, Koch L, Edimiris P, Nießen S, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.

Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:124-9. doi: 10.1016/j.ejogrb.2014.07.029. Epub 2014 Aug 4.

PMID:
25150949
46.

Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.

Tewes M, Kasimir-Bauer S, Welt A, Schuler M, Kimmig R, Aktas B.

J Cancer Res Clin Oncol. 2015 Jan;141(1):87-92. doi: 10.1007/s00432-014-1784-2. Epub 2014 Aug 10.

PMID:
25108406
47.

ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.

Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2014 Oct;60(10):1282-9. doi: 10.1373/clinchem.2014.224808. Epub 2014 Jul 11.

48.

Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome.

Köninger A, Koch L, Edimiris P, Enekwe A, Nagarajah J, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.

Arch Gynecol Obstet. 2014 Nov;290(5):1023-30. doi: 10.1007/s00404-014-3317-2. Epub 2014 Jun 25.

PMID:
24961320
49.

Serum concentrations of afamin are elevated in patients with polycystic ovary syndrome.

Köninger A, Edimiris P, Koch L, Enekwe A, Lamina C, Kasimir-Bauer S, Kimmig R, Dieplinger H.

Endocr Connect. 2014 Sep;3(3):120-6. doi: 10.1530/EC-14-0053. Epub 2014 Jun 13.

50.

Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.

Wimberger P, Chebouti I, Kasimir-Bauer S, Lachmann R, Kuhlisch E, Kimmig R, Süleyman E, Kuhlmann JD.

Gynecol Oncol. 2014 Jun;133(3):467-72. doi: 10.1016/j.ygyno.2014.03.574. Epub 2014 Apr 5.

PMID:
24713547

Supplemental Content

Loading ...
Support Center